VusionGroup has announced the resignation of Ms. Rong Huang, a director affiliated with BOE, amid a reduction in BOE's shareholding from 32% to 25%. The company aims to fortify its governance by ...

On May 13, 2025, Renault Group, through its Mobilize brand, and Autostrade per l'Italia (ASPI), through Free To X, finalized a strategic alliance. This collaboration aims to develop the fast-charging ...

For the first quarter of 2025, Groupe Beneteau reported revenues of €130 million, a decrease of 43% compared to the same period last year. The decline is attributed to reduced demand across boat ...

Swissnet Group has announced its preliminary unaudited financial results for FY2024, showcasing significant growth aligned with previous guidance. The company's revenue reached CHF 13.1 million, ...

Formycon AG and Fresenius Kabi have announced the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar, in Canada. This product is available in both subcutaneous and intravenous ...

On May 27, 2025, Lonza Group AG released its 2024 comparative financials, reflecting the new One Lonza organizational structure effective from April 1, 2025. This structure features three CDMO ...

At the Annual General Meeting on May 23, 2025, Ernst Russ AG saw significant management changes and shareholder approvals in Hamburg. All agenda points were resolved with strong support for management ...

Delta Plus Group reported revenue of €94.6 million in the first quarter of 2025, down 1.3% year-on-year. This decline amounts to 2.4% at constant scope and exchange rates. The company, which ...

On 27 May 2025, Nordex Group announced receiving two significant contracts for wind turbine installation in France. The contracts involve the supply of 13 wind turbines, including six N163/5.X, six ...

Bureau Veritas has issued a press release regarding the share buyback carried out between May 8 and 9, 2025. During this period, the company acquired a total of 819,703 shares. These transactions were ...

Formycon AG and Fresenius Kabi announced that the U.S. FDA has granted interchangeability for FYB202/Otulfi® (ustekinumab-aauz) with Stelara®. Effective April 2025, Otulfi® can be substituted without ...

GENFIT, a biopharmaceutical company, announced its financial results for the first quarter of 2025. Cash and cash equivalents as of March 31, 2025, stood at €129.5 million, compared to €74.0 million a ...